The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Guest Editorial

AACR: 21st Century Cures a “Model for An Open and Honest Conversation”

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

Almost one year ago (on April 30, 2014), House Energy and Commerce Committee Chairman Fred Upton (R-Mich.), along with Oversight and Investigations Subcommittee Ranking Member Diana DeGette (D-Colo.) announced the launch of 21st Century Cures, an initiative aimed at accelerating the pace of cures and medical breakthroughs in the United States by ensuring that our laws are keeping pace with innovation.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
José Baselga
President, American Association for Cancer Research; Physician-in-chief, chief medical officer, Memorial Sloan Kettering Cancer Center
William S. Dalton
Chair, AACR Science Policy & Government Affairs Committee; chief executive officer, M2Gen; Director, DeBartolo Family Personalized Medicine Institute, Moffitt Cancer Center
Table of Contents

YOU MAY BE INTERESTED IN

ClinicalTrials & Tribulations

How GLP-1RA drugs are reshaping patient physiology and the future of oncology

The rapid adoption of glucagon-like peptide-1 receptor agonists (GLP-1RAs), particularly for weight management, represents one of the most significant shifts in metabolic medicine in decades. With millions of people now using medications such as semaglutide and tirzepatide, we are witnessing a fundamental alteration in patient physiology that extends far beyond glucose control and weight loss. As these drugs approach 10% population penetrance in some demographics, the oncology community faces an urgent question: How will this metabolic transformation reshape cancer care?
By Deborah Phippard
Byline
José Baselga
President, American Association for Cancer Research; Physician-in-chief, chief medical officer, Memorial Sloan Kettering Cancer Center
William S. Dalton
Chair, AACR Science Policy & Government Affairs Committee; chief executive officer, M2Gen; Director, DeBartolo Family Personalized Medicine Institute, Moffitt Cancer Center
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account